Key result
Acute transcutaneous auricular vagus nerve stimulation does not alter vagally mediated heart rate variability compared to sham in healthy participants (g = 0.014; CI -0.103 to 0.132; BF01 = 24.678).
Why the study?
The neurophysiological mechanisms of taVNS are not fully understood, and the replicability of findings regarding its effects on candidate biomarkers like vmHRV has been questioned.
Does acute transcutaneous auricular vagus nerve stimulation alter vagally mediated heart rate variability in healthy participants?
Meta-Analysis
Single-blind
Does acute transcutaneous auricular vagus nerve stimulation alter vagally mediated heart rate variability in healthy participants?
Standardized Mean Difference: 0.014 (95% CI -0.103–0.132)
Acute transcutaneous auricular vagus nerve stimulation does not alter vagally mediated heart rate variability, suggesting it is not a robust biomarker for taVNS effects.
Acute taVNS should not be expected to alter HRV in healthy adults; challenges its validity as a vagal biomarker and supports alternative endpoints in trials.
Non‐invasive brain stimulation techniques, such as transcutaneous auricular vagus nerve stimulation (taVNS), have considerable potential for clinical use. Beneficial effects of taVNS have been demonstrated on symptoms in patients with mental or neurological disorders as well as transdiagnostic dimensions, including mood and motivation. However, since taVNS research is still an emerging field, the underlying neurophysiological processes are not yet fully understood, and the replicability of findings on biomarkers of taVNS effects has been questioned. The objective of this analysis was to synthesize the current evidence concerning the effects of taVNS on vagally mediated heart rate variability (vmHRV), a candidate biomarker that has, so far, received most attention in the field. We performed a living Bayesian random effects meta‐analysis. To keep the synthesis of evidence transparent and up to date as new studies are being published, we developed a Shiny web app that regularly incorporates new results and enables users to modify study selection criteria to evaluate the robustness of the inference across potential confounds. Our analysis focuses on 16 single‐blind studies comparing taVNS versus sham in healthy participants. The meta‐analysis provides strong evidence for the null hypothesis ( g = 0.014, CI shortest = [−0.103, 0.132], BF 01 = 24.678), indicating that acute taVNS does not alter vmHRV compared to sham. To conclude, there is no support for the hypothesis that vmHRV is a robust biomarker for acute taVNS. By increasing transparency and timeliness, the concept of living meta‐analyses can lead to transformational benefits in emerging fields such as non‐invasive brain stimulation.
No takes yet. Share an insight, caveat, or question.
Wolf et al. (2021) conducted a meta-analysis in Healthy participants. Transcutaneous auricular vagus nerve stimulation (taVNS) vs. Sham was evaluated on Vagally mediated heart rate variability (vmHRV) (g = 0.014, 95% CI -0.103 to 0.132). Acute transcutaneous auricular vagus nerve stimulation does not alter vagally mediated heart rate variability compared to sham in healthy participants (g = 0.014; CI -0.103 to 0.132; BF01 = 24.678).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: